Therefore, inhibition of GSK-3β may provide indirect benefits for the treatment of osteosarcoma by limiting the extent of chemotherapy-associated bone marrow injury and by preserving tumor-adjacent stromal cells. This evidence concerns the gene GSK3B and neoplasm.